

(FILE 'HOME' ENTERED AT 17:29:38 ON 08 AUG 2002)

FILE 'CAPLUS, BIOSIS, EMBASE, MEDLINE' ENTERED AT 17:29:56 ON 08 AUG 2002

L1	88125 S ADENOVIR?
L2	33472 S L1 AND PY<1991
L3	4670 S L2 AND EXPRESS?
L4	2637 S L3 AND (DNA OR CDNA)
L5	1172 DUP REM L4 (1465 DUPLICATES REMOVED)
L6	909 S L5 AND PY>1982
L7	392 S L6 AND PROMOTER
L8	65 S L7 AND SV40
L9	65 DUP REM L8 (0 DUPLICATES REMOVED) E PERRICAUDET MICHEL/AU
L10	740 S E1-4
L11	579 S L10 AND ADENOVIR?
L12	91 S L11 AND PY<1990
L13	113 S L11 AND PY<1991

L Number	Hits	Search Text	DB	Time stamp
1	1	6410010.pn.	USPAT; US-PGPUB; EPO; JPO	2002/08/08 14:40
2	57576	6410010.pn. and actin promoter	USPAT; US-PGPUB; EPO; JPO	2002/08/08 14:40
3	0	6410010.pn. and actin adj promoter	USPAT; US-PGPUB; EPO; JPO	2002/08/08 14:43
4	1	6410010.pn. and sv40 adj promoter	USPAT; US-PGPUB; EPO; JPO	2002/08/08 14:40
5	0	6410010.pn. and RSV adj promoter	USPAT; US-PGPUB; EPO; JPO	2002/08/08 14:40
6	1	6410010.pn. and actin adj promoter\$1	USPAT; US-PGPUB; EPO; JPO	2002/08/08 15:30
7	1	6410010.pn. and wild adj type adj p53	USPAT; US-PGPUB; EPO; JPO	2002/08/08 15:34
8	1	6410010.pn. and cmv	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:19
9	11881	adenovir\$2	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:19
10	801	adenovir\$2 same cmv adj promoter	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:24
11	15	(adenovir\$2 same cmv adj promoter) same p53	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:24
12	1893	adenovir\$2 same rsv	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:25
13	5	(adenovir\$2 same rsv) same p53	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:25
14	4393	adenovir\$2 same sv40	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:25
15	109	(adenovir\$2 same sv40) same p53	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:25
16	1192	adenovir\$2 same actin	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:26
17	12	(adenovir\$2 same actin) same p53	USPAT; US-PGPUB; EPO; JPO	2002/08/08 17:26

(FILE 'HOME' ENTERED AT 17:29:38 ON 08 AUG 2002)

FILE 'CAPLUS, BIOSIS, EMBASE, MEDLINE' ENTERED AT 17:29:56 ON 08 AUG 2002

L1 88125 S ADENOVIR?
L2 33472 S L1 AND PY<1991
L3 4670 S L2 AND EXPRESS?
L4 2637 S L3 AND (DNA OR CDNA)
L5 1172 DUP REM L4 (1465 DUPLICATES REMOVED)
L6 909 S L5 AND PY>1982
L7 392 S L6 AND PROMOTER
L8 65 S L7 AND SV40
L9 65 DUP REM L8 (0 DUPLICATES REMOVED)
E PERRICAUDET MICHEL/AU
L10 740 S E1-4
L11 579 S L10 AND ADENOVIR?
L12 91 S L11 AND PY<1990
L13 113 S L11 AND PY<1991
L14 1 S L7 AND CMV
L15 11439 S L1 AND PROMOTER
L16 1037 S L15 AND CMV
L17 65 S L16 AND P53
L18 34 DUP REM L17 (31 DUPLICATES REMOVED)
L19 11 S L2 AND GENE THERAPY
L20 8 DUP REM L19 (3 DUPLICATES REMOVED)
L21 4125 S L1 AND P53
L22 7 S L21 AND RSV PROMOTER
L23 4 DUP REM L22 (3 DUPLICATES REMOVED)
L24 4 S L21 AND SV40 PROMOTER
L25 4 DUP REM L24 (0 DUPLICATES REMOVED)
L26 0 S L21 AND BETA ACTIN PROMOTER
L27 292 S L21 AND SV40
L28 65 S L27 AND PROMOTER
L29 35 DUP REM L28 (30 DUPLICATES REMOVED)

L23 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

AN 1998:344524 CAPLUS

DN 129:13217

TI Diminishing viral gene expression by promoter replacement in
adenoviral vectors

IN Fang, Bingliang; Roth, Jack A.

PA Board of Regents, The University of Texas System, USA; Fang, Bingliang;
Roth, Jack A.

SO PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9821350	A1	19980522	WO 1997-US20608	19971112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR,				
	KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,				
	US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	AU 9852539	A1	19980603	AU 1998-52539	19971112
	US 6110744	A	20000829	US 1997-968014	19971112
PRAI	US 1996-30675P	P	19961113		